[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Group: FINLAY-FR-2; 25 \u00b5g of RBD-TT / alumina; Intramuscular (IM); 0.5 mL; 0 - 28 days. Presentation: Vial with single dose / Vial with multidose of 10 doses + FINLAY-FR-1A; 50 \u00b5g of d-RBD / alumina; Intramuscular (IM); 0.5 mL as a 56-day booster dose. Presentation: Vial with single dose; Immunogenicity; Vaccine ;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Finlay FR 2 25 \u00b5g+Finlay FR 1A 50 \u00b5g;2+1;days 0-28 + day 56;IM (third dose)", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]